6375 results for "11+1双色球多少钱一注"

in 8.36 milliseconds.

• Transcriptome of (peripheral blood), from donor Sample A, replicate 1 FACS processing technical replicates

  FACS processing technical replicates

  Dataset EGAD00001010086

• Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies

  Purpose: To evaluate the safety, efficacy, pharmacokinetics, pharmacodynamics, and biomarker data of linrodostat mesylate, a selective, oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, combined with nivolumab ± ipilimumab in advanced solid tumors and hematologic malignancies. Patients and Methods: In this phase 1/2 study, patients received once-daily (QD) linrodostat (part 1 [escalation], 25-400 mg; part 2 [expansion], 100 or 200 mg) plus nivolumab (480 mg every [Q] 4 weeks [W] or 240 mg Q2W) or triplet therapy (part 3, linrodostat 20-100 mg QD; nivolumab 360 mg Q3W or 480 mg Q4W; ipilimumab 1 mg/kg Q6W or Q8W). Endpoints included safety and efficacy (co-primary; parts 2, 3), pharmacokinetics, pharmacodynamics, biomarkers, and efficacy (part 1). Results: Fifty-five, 494, and 41 patients were enrolled in parts 1, 2, and 3, respectively. Linrodostat exposures exceeded predicted therapeutic target concentrations starting at 50 mg. Rates of grade 3/4 adverse events were 50.1%-63.4%. The maximum tolerated linrodostat dose was 200 mg; dose-limiting toxicities were primarily immune related. Responses were observed across different cohorts, study parts, and tumor types, particularly in immunotherapy-naive patients. Kynurenine decreased with linrodostat + nivolumab, regardless of response. In contrast, interferon gamma (IFN-γ) gene expression signature was associated with response; in nonmelanoma patients, a composite of low tryptophan 2,3-dioxygenase (TDO2) gene expression plus high IFN-γ signature was associated with response. Conclusions: Linrodostat + nivolumab ± ipilimumab demonstrated a manageable safety profile. Kynurenine changes supported IDO1 pathway inhibition but did not correlate with response. A composite biomarker of low TDO2 expression plus high IFN-γ gene expression may predict response to linrodostat + nivolumab.

  Study EGAS50000000710

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells - untreated) from donor D3, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008057

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells - untreated) from donor D1, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008037

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells - untreated) from donor D2, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008047

• Targeted capture ctDNA Library CRCQV42Run021-16

  Targeted capture ctDNA Library CRCQV42Run021-16 from patient PBC0001470, plasma 1 month sample

  Dataset EGAD00001010438

• Acute myeloid leukemia sequencing data

  This study contains tumor DNA and RNA sequencing data for 1 AML patient

  Study EGAS00001006354

• ChIP seq samples

  Dataset contains 12 ChIP-Seq samples sequenced on the Illumina NextSeq500 sequencer. 3 samples are control samples (HcAct-Chip 1,HcAct-Chip 2,HcAct-Imput 2) 9 samples are case samples (HcAct2DG-Chip 1,HcAct2DG-Chip 2,HcAct2DG-Imput 1,JIAAct-Chip1,JIAAct-Chip2,JIAAct-Imput2,JIAAct2DG-Chip1,JIAAct2DG-Chip2,JIAAct2DG-Imput2)

  Dataset EGAD50000001188

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Resveratrol from donor D3, replicate 1, glucose concentration 5mM

  Dataset EGAD00001008059

• Transcriptome of human CD4+ T-lymphyocyte (memory-T-cells) treated with Oligomycin from donor D2, replicate 1, glucose concentration 1mM

  Dataset EGAD00001008055